enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA-approved drug for ulcerative colitis also effective for ...

   www.aol.com/fda-approved-drug-ulcerative-colitis...

   Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, also sends Crohn's disease into clinical remission, new findings suggest.

3. Vedolizumab - Wikipedia

   en.wikipedia.org/wiki/Vedolizumab

   Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Takeda Oncology for the treatment of ulcerative colitis and Crohn's disease. [5] It binds to integrin α 4 β 7 ( LPAM-1 , lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7 ), [ 5 ] [ 6 ] blocking the α 4 ...

4. Mirikizumab - Wikipedia

   en.wikipedia.org/wiki/Mirikizumab

   Mirikizumab was developed by Eli Lilly and Company. [10]The approval was based on the LUCENT 1 clinical study which evaluated the safety and efficacy of mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

5. Etrasimod - Wikipedia

   en.wikipedia.org/wiki/Etrasimod

   Etrasimod, sold under the brand name Velsipity, is a medication that is used for the treatment of ulcerative colitis. [6] It is a selective sphingosine-1-phosphate (S1P) receptor modulator that modifies the activity of the immune system. [6] It is taken by mouth. [6] The most common side effects include lymphopenia (low levels of lymphocytes ...

6. Ozanimod - Wikipedia

   en.wikipedia.org/wiki/Ozanimod

   Touchstone is a double-blind, placebo controlled phase II clinical for the treatment of ulcerative colitis. [ 24 ] [ 25 ] 197 patients, ages 18–75, with moderate to severe ulcerative colitis (Mayo Score 6–10) were recruited and assigned either placebo, 0.5 mg or 1 mg of oral ozanimod followed by 1 week of dose escalation.

7. Targeted therapy may help treat moderate to severe ulcerative ...

   www.aol.com/targeted-therapy-may-help-treat...

   An anti-TL1A monoclonal antibody called tulisokibart may help people with moderate to severe ulcerative colitis achieve clinical remission, a phase 2 trial has found.